Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

Strategic Priorities for 2025 - The company aims to expand access to KIMMTRAK for metastatic uveal melanoma (mUM) patients globally through additional launches and increased community penetration, building on 38 country approvals and 23 launches as of year-end 2024 [1][7] - Three Phase 3 trials are enrolling across multiple melanoma indications, with the first topline results expected in 2026, potentially addressing up to 15,000 additional patients across three new melanoma indications [1][8] - The company plans to present initial HIV Phase 1 MAD data in Q1 2025 and advance autoimmune candidates, including a CTA submission for a Type 1 diabetes candidate in 2025 [1][6][15] Melanoma Franchise Expansion - KIMMTRAK, the world's first bispecific TCR therapy, is available in 23 countries, with ongoing Phase 3 trials in melanoma and a brenetafusp Phase 3 trial in first-line melanoma [4][7] - The company is enrolling patients in three registrational Phase 3 trials: TEBE-AM, PRISM-MEL-301, and ATOM, targeting up to 4,000, 10,000, and 1,200 patients respectively [12] - The company will continue to highlight three-year overall survival data for KIMMTRAK in launched countries [7] Clinical Portfolio Advancements - The company is enrolling patients in multiple Phase 1/2 trials, including brenetafusp combinations in ovarian and lung cancer, and dose escalation trials with IMC-R117C (PIWIL1) and IMC-P115C (PRAME-A02-HLE) [1][9][10] - A Phase 1/2 trial is evaluating brenetafusp in platinum-resistant ovarian cancer (PROC) and platinum-sensitive ovarian cancer (PSOC), as well as in metastatic non-small cell lung cancer (NSCLC) cohorts [9] - The company is also enrolling patients in a Phase 1 trial with IMC-P115C (PRAME-A02-HLE) in multiple solid tumors, designed to reduce treatment administration frequency [10] Infectious Diseases Pipeline - The company is enrolling people living with HIV (PLWH) in the Phase 1 MAD trial with IMC-M113V, aiming to identify a safe dosing schedule and explore higher doses for a potential functional cure [5][12] - Initial data from the Phase 1 trial with IMC-I109V for hepatitis B virus (HBV) will be presented in 2025 [5] Autoimmune Diseases Innovation - The company is advancing two autoimmune candidates: IMC-S118AI (PPI x PD1) for Type 1 diabetes, with a CTA submission planned for 2025, and IMC-U120AI (CD1a x PD1) for atopic dermatitis, with a CTA submission planned for 2026 [6][15][16] - IMC-U120AI is the company's first non-HLA restricted candidate, targeting CD1a for atopic dermatitis and potentially other immune diseases [16] Corporate Updates - Travis Coy was appointed Executive Vice President, Chief Financial Officer, and Head of Corporate Development in January 2025, bringing over 20 years of experience from Eli Lilly and Company [17] - The company's preliminary unaudited cash position as of December 31, 2024, was approximately $820 million, with final financial results to be reported in late February 2025 [18] Technology and Platform Overview - The company's ImmTAC platform generates bispecific biologics designed to redirect the immune system to recognize and kill cancerous cells, with potential applications in hematologic and solid tumors [20] - ImmTAV molecules target virally infected cells, aiming for functional cures in HIV and HBV [21][22] - ImmTAAI molecules are designed for tissue-specific immune modulation, with candidates in development for Type 1 diabetes and inflammatory dermatological diseases [23]